Law360, New York (September 20, 2006, 12:00 AM EDT) -- Massachusetts-based biopharmaceutical company Avant Immunotherapeutics Inc. said on Wednesday that GlaxoSmithKline has been paying the lower of two royalty rates on its sales for a rotavirus vaccine in Australia and several European countries under a license agreement between the two companies dating back to 1997.
GlaxoSmithKline told Avant that the vaccine, Rotarix, is not covered by the licensed patents in Australia and the other European countries, the biopharmaceutical said. Regardless, Avant is continuing to look into the claims, it said.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.